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gAOBJECTIVES The aim of this study was to analyze whether scar characterization could improve the risk stratification for
life-threatening ventricular arrhythmias and sudden cardiac death (SCD).
BACKGROUND Among patients with a cardiac resynchronization therapy (CRT) indication, appropriate defibrillator
(CRT-D) therapy rates are low.
METHODS Primary prevention patients with a class I indication for CRT were prospectively enrolled and assigned to
CRT-D or CRT pacemaker according to physician’s criteria. Pre-procedure contrast-enhanced cardiac magnetic resonance
was obtained and analyzed to identify scar presence or absence, quantify the amount of core and border zone (BZ), and
depict BZ distribution. The presence, mass, and characteristics of BZ channels in the scar were recorded. The primary
endpoint was appropriate defibrillator therapy or SCD.
RESULTS 217 patients (39.6% ischemic) were included. During a median follow-up of 35.5 months (12 to 62 months),
the primary endpoint occurred in 25 patients (11.5%) and did not occur in patients without myocardial scar. Among
patients with scar (n ¼ 125, 57.6%), those with implantable cardioverter-defibrillator (ICD) therapies or SCD exhibited
greater scar mass (38.7  34.2 g vs. 17.9  17.2 g; p < 0.001), scar heterogeneity (BZ mass/scar mass ratio) (49.5  13.0
vs. 40.1  21.7; p ¼ 0.044), and BZ channel mass (3.6  3.0 g vs. 1.8  3.4 g; p ¼ 0.018). BZ mass (hazard ratio: 1.06
[95% confidence interval: 1.04 to 1.08]; p < 0.001) and BZ channel mass (hazard ratio: 1.21 [95% confidence interval:
1.10 to 1.32]; p < 0.001) were the strongest predictors of the primary endpoint. An algorithm based on scar mass and
the absence of BZ channels identified 148 patients (68.2%) without ICD therapy/SCD during follow-up with a 100%
negative predictive value.
CONCLUSIONS The presence, extension, heterogeneity, and qualitative distribution of BZ tissue of myocardial scar
independently predict appropriate ICD therapies and SCD in CRT patients. (J Am Coll Cardiol Img 2017;-:-–-)
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ABBR EV I A T I ON S
AND ACRONYMS
3D = 3-dimensional
ATP = antitachycardia pacing
AUC = area under the curve
BZ = border zone











HR = hazard ratio
ICD = implantable
cardioverter-defibrillator
LV = left ventricle/ventricular
LVEF = left ventricular ejection
fraction
MPSI = maximum pixel signal
intensity
NYHA = New York Heart
Association
PP = primary prevention
SCD = sudden cardiac death
VA = ventricular arrhythmia
VT = ventricular tachycardia
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C ardiac resynchronization therapy(CRT), with or without an implant-able defibrillator (CRT-D), reduces
mortality and improves cardiac function in
symptomatic chronic heart failure patients
with depressed left ventricular ejection frac-
tion (LVEF) and prolonged QRS duration
(1,2). The survival benefit of CRT-D over a
CRT pacemaker (CRT-P) is not well estab-
lished. Current guidelines recommend
CRT-D or CRT-P implantation in primary pre-
vention (PP) patients with the same level of
evidence (3). Most PP patients with CRT indi-
cation receive a CRT-D, although only aminor-
ity of these individuals (15% to 18%) require
implantable cardioverter-defibrillator (ICD)
therapies during follow-up (1,4). Therefore,
better risk-stratification tools are required in
order to identify those CRT patients at high
risk of life-threatening ventricular arrhyth-
mias (VAs) that could benefit from CRT-D
implantation.
Myocardial scar provides the substrate for
VAs. Contrast-enhanced cardiac magnetic
resonance (ce-CMR) allows an accurate
identification and quantification of myocar-
dial scar tissue, and enables the differentia-
tion between the scar core and border zone
(BZ) (5–7). Although several studies have
shown the utility of scar characterization for
risk stratification of VAs in ICD patients (5,6),its role in CRT patients is less well defined. The issue
of scar characterization for risk stratification of VAs in
CRT patients becomes especially interesting given
that CRT response has been associated with a
reduction of the risk of VA (2); however, it remains
unknown whether this is influenced by the presence/
absence of scar and its characteristics. We conducted
a multicenter study with long-term follow-up to
test the hypothesis that scar characterization by
ce-CMR could improve the risk stratification oflinic, University of Barcelona, Barcelona, Catalonia, Spain; iGalgo
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METHODS
STUDY DESIGN AND POPULATION. This was a pro-
spective, observational multicenter study. Consecu-
tive PP patients with heart failure, dilated
cardiomyopathy, LVEF <35%, and wide QRS (>120 ms)
whowere referred for CRTwere prospectively enrolled
at 6 centers in Barcelona (Spain). The type of CRT (CRT-
D vs. CRT-P) was decided according to physician’s
criteria before study inclusion. ce-CMRwas performed
before device implantation to assess left ventricular
(LV) function and to identify and characterize scar
tissue. Patients with contraindications to ce-CMR or
those in whom ce-CMR could not be performed due to
logistical reasons were excluded. Patients with diag-
nosis of noncompaction cardiomyopathy were also
excluded due to its intrinsic arrhythmogenic capabil-
ities and the impossibility of appropriate segmentation
on noncompacted areas. After implantation, 2-zone
detection was programmed in all patients: fast ven-
tricular tachycardia (VT) (170 to 220 beats/min) and
ventricular fibrillation (>220 beats/min). Supraven-
tricular tachycardia discrimination algorithms were
programmed for the VT zone. In all CRT-D patients,
shock (plus antitachycardia pacing [ATP] during
charging when possible) was programmed in the ven-
tricular fibrillation zone. Programming or not ICD
therapies in the fast VT zone was left to the discretion
of the treating physician. The fast-VT zone therapywas
ATP at 91% and 81% of tachycardia cycle length with
10-ms scan followed by shocks.
All patients provided written informed consent to
participate. The local ethics committee approved this
study.
CONTRAST-ENHANCED CMR. The ce-CMR study was
performed either using a 1.5-T (n ¼ 144, 66.4%) or a
3-T (n ¼ 73, 33.6%) clinical scanner. See the Online
Appendix for details.Medical, SL, Barcelona, Spain; jSiemens Healthcare
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(A) Short-axis view, 2-chamber view, and 4-chamber view of contrast-enhanced magnetic resonance showing a transmural scar in the anterior wall of the left ventricle.
(B) Concentric layers from the endocardium to epicardium were created and were color-coded according to signal intensity (normal myocardium is in purple, border
zone in green, and core in red). (C) 3-Dimensional color-coded signal intensity maps in 5 transmural shells were obtained representing the scar, shape, and distribution
of the scar tissue across the wall thickness.
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Myocardial scar quantification and characterization. All
ce-CMR images were analyzed with the segmentation
program TCTK (Tissue Characterization Tool Kit,
Barcelona, Spain) in a central core lab. An experi-
enced observer, blinded to the clinical data, delin-
eated the myocardial fibrosis region in all short-axis
slices. The myocardial-fibrosis tissue was divided into
core and BZ using an algorithm based on maximum
pixel signal intensity (MPSI). The core was defined as
a region with signal intensity >60% of MPSI in the
scar area, whereas BZ was established as the region
with signal intensity <60% and >40% of MPSI, as
previously described (8). Total core and BZ mass were
obtained by multiplying the number of the
voxels of each region by voxel mass, as previously
described (9).
Identification of BZ channels. Identification of BZ
channels was performed in a central core lab. Usingan investigational software tool (ADAS, Galgo Medical
SL, Barcelona, Spain), a 3-dimensional (3D) model of
the LV showing endocardial and epicardial borders
was obtained using a semiautomated segmentation
algorithm. Once the model was obtained, 5 concentric
surface layers from the endocardium to epicardium
were created (10%, 25%, 50%, 75%, and 90% of the LV
wall thickness).
Using the same thresholds described previously to
differentiate the scar core from the BZ and the BZ
from the healthy tissue, 3D color-coded signal in-
tensity maps in the 5 transmural shells were obtained
representing the scar shape and distribution of the
scar tissue (characterized into core and BZ) across the
wall thickness (Figure 1).
A BZ channel in the ce-CMR reconstruction was
defined as a corridor of BZ connecting 2 areas of
normal myocardium flowing between 2 core areas or
FIGURE 2 BZ Channel Mass Calculation
CHANNEL 2
CHANNEL 2
A white line is drawn over the surface extending between normal myocardium zones and used as the centerline of a 5-mm radius tube
extending beyond the surface (right). This tube enclosed the BZ voxels of the original ce-CMR image that will contribute to the BZ channel
mass. BZ ¼ border zone; ce-CMR ¼ contrast-enhanced cardiac magnetic resonance.






(n ¼ 63) p Value*
Age, yrs 65.1  10.5 63.3  10.8 69.5  8.3 <0.001
Male 156 (71.9) 124 (80.5) 32 (50.8) <0.001
Ischemic cardiomyopathy 86 (39.6) 70 (45.5) 16 (25.4) 0.006
NYHA functional class 0.537
II 77 (35.5) 56 (36.4) 21 (33.3)
III 130 (59.9) 92 (59.7) 38 (60.3)
IV 9 (4.1) 5 (3.2) 4 (6.3)
LVEF, % 26.02  8.04 25.2  7.7 28.08  8.5 0.018
LVESV, ml 242.5  113.8 249.0  109.5 224.2  124.5 0.190
Diabetes 64 (29.5) 43 (27.9) 21 (33.3) 0.621
Atrial fibrillation 40 (18.4) 27 (17.5) 13 (20.6) 0.562
GFR, ml/min 72.2  27.0 75.7  27.5 63.6  23.9 0.005
6MWT, m 297.3  202.3 306.6  137.2 266.9  88.3 0.145
QRS duration, ms 161.7  30.3 161.2  31.6 162.8  27.7 0.747
Medication
b-blocker 163 (75.1) 117 (75.9) 46 (73.0) 0.707
ACEI/ARB 168 (77.4) 112 (72.7) 44 (69.8) 0.722
Spironolactone 103 (47.5) 71 (46.1) 32 (50.7) 0.875
Diuretic 133 (61.3) 87 (56.4) 46 (73.0) 0.223
Digoxin 32 (14.7) 17 (11.0) 15 (23.0) 0.107
Amiodarone 22 (10.1) 16 (10.3) 6 (9.5) 1.00
Values are mean  SD or n (%). *CRT-D versus CRT-P groups comparison.
6MWT ¼ 6-min walk test; ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor
blocker; CRT-D ¼ cardiac resynchronization therapy with defibrillator; CRT-P ¼ cardiac resynchronization therapy
with pacemaker; GFR ¼ glomerular filtration rate; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ven-
tricular end-systolic volume; NYHA ¼ New York Heart Association.
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between a core area and a valve annulus (Figure 2) (8).
An electrophysiologist, blinded to the clinical results,
analyzed the 3D reconstructions and identified the BZ
channels according to their distribution across the
whole LV wall thickness. If the image quality of any
set of images was too low to be reconstructed (the
presence of artifacts or moderate/severe slice shift-
ing), the set was considered unreadable. Once iden-
tified, the BZ channels were manually delineated by
drawing a line between areas of normal myocardium.
Finally, the BZ channel mass was calculated by
multiplying the number of voxels within the BZ
channels by voxel mass (Figure 2). See the Online
Appendix for details.
FOLLOW-UP AND ENDPOINTS. Clinical evaluation
was performed before device implantation and every
6 months thereafter. Device interrogation was per-
formed at 1 month after implantation and every 6
months thereafter. The primary endpoint was defined
as the composite of appropriate ICD therapy (classi-
fied as ATP or shock) or SCD, in order to include all
potential life-threatening VAs observed in the study
cohort. Inappropriate ICD therapy was recorded. All
device interrogations were blinded to ce-CMR results,
and all events were reviewed by an event review
committee. Echocardiographic and clinical parame-
ters, including LVEF, LV diameters, and New York
Heart Association (NYHA) functional class, were







(95% CI) p Value*
Age, yrs 63.2  14.6 65.1  9.9 0.97 (0.94–1.01) 0.09
Male 22 (88.0) 56 (30.1) 3.66 (1.12–12.65) 0.03
Ischemic cardiomyopathy 13 (52.0) 72 (38.7) 1.62 (0.74–3.54) 0.23
NYHA functional class 0.62 (0.41–1.16) 0.24
II 9 (36.0) 67 (36.0)
III 14 (56.0) 111 (59.7)
IV 1 (4.0) 8 (4.3)
Baseline LVEF, % 26.1  8.1 26.2  7.3 0.99 (0.94–1.04) 0.60
12-month LVEF, % 30.6  9.3 36.5  10.9 0.95 (0.89–1.01) 0.131
Baseline LVESV, ml 255.8  108.5 237.5  111.8 1 (0.99–1.01) 0.19
12-month LVESV, ml 166.8  81.0 126.0  84.0 1 (0.99–1.01) 0.605
Diabetes 4 (16.0) 58 (31.2) 0.49 (0.17–1.47) 0.21
Atrial fibrillation 5 (20.0) 34 (18.2) 1.17 (0.44–3.12) 0.75
GFR, ml/min 79.7  33.8 71.3  25.9 1.01 (0.99–1.03) 0.1
QRS duration, ms 163.7  25.9 161.2  31.4 1 (0.99–1.01) 0.93
Medication
b-Blocker 17 (68.0) 141 (75.8) 0.55 (0.23–1.34) 0.19
ACEI/ARB 16 (64.0) 135 (72.5) 0.62 (0.26–1.45) 0.27
Spironolactone 9 (36.0) 91 (48.9) 0.80 (0.34–1.87) 0.61
Diuretic 15 (60.0) 114 (61.2) 0.61 (0.28–1.44) 0.26
Digoxin 3 (12.0) 28 (15.0) 0.75 (0.22–2.56) 0.653
Amiodarone 1 (4.0) 21 (11.2) 0.41 (0.05–3.04) 0.382
Values are mean  SD or n (%). Competing risk regression analysis by cause-specific hazard model for the pri-
mary endpoint is shown. *ICD Therapy/SCD versus No ICD Therapy/SCD group comparison.
CI ¼ confidence interval; HR ¼ hazard ratio; ICD ¼ implantable cardioverter-defibrillator; other abbreviations
as in Table 1.





(n ¼ 186) p Value*
Scar mass, g 38.7  34.2 17.9  17.2 <0.001
BZ mass, g 20.0  22.5 8.7  10.8 <0.001
BZ mass/scar mass ratio 0.49  0.13 0.4  0.21 0.044
Core mass, g 19.0  14.2 9.3  8.7 <0.001
BZ channel mass, g 3.6  3.0 1.8  3.4 <0.001
Values are mean  SD. *ICD Therapy/SCD versus No ICD Therapy/SCD group
comparison.
BZ ¼ border zone; ce-CMR ¼ contrast-enhanced cardiac magnetic resonance;
ICD ¼ implantable converter-defibrillator; SCD ¼ sudden cardiac defibrillator.
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reassessed at 12-month follow-up. Furthermore, total
mortality and cardiac mortality were analyzed. The
composite of cardiac mortality, SCD, and appropriate
ICD therapy was considered as a secondary endpoint.
STATISTICAL ANALYSIS. Continuous data are re-
ported as mean  SD, and comparisons between
groups were performed using the Student t test or
Mann-Whitney U test, as appropriate. Categorical
variables are presented as frequencies (percentages)
and compared with the chi-square test or Fisher exact
method. Receiver-operating characteristic curves
were performed to estimate the predictive value of
scar variables and to identify cutoff points of interest.
For the competing risk analysis, we tabulated the
number of patients with each of the 3 outcomes of
interest (appropriate ICD therapy, SCD, and death
from any other cause). Due to the presence of
competing risks, to analyze the effect of baseline
predictors on the primary endpoint (appropriate ICD
therapy or SCD), we used the cause-specific hazard
model for analyzing competing risk survival data as
previously described by Austin et al. (10). Variables
selected in the univariate analyses (p < 0.05) and
those considered clinically relevant (LVEF and NYHA
functional class, because of its established prognostic
value) were entered into multivariate cause-specific
hazards models to estimate the independent effect
of the scar tissue characteristics on event-free sur-
vival for both the primary and secondary endpoints.
Scar-related variables were included separately in the
multivariate analysis because they were strongly
related, and therefore, different multivariate models
were needed. Cumulative incidence functions for the
primary endpoint and competitive events are pro-
vided. For all tests, a p value <0.05 was considered
statistically significant. Analysis was performed
using SPSS 17.0 software (IBM, Armonk, New York)
and R version 3.3.1 (R Foundation for Statistical
Computing, Vienna, Austria).
RESULTS
PATIENT POPULATION. Baseline characteristics. A
cohort of 235 consecutive patients with class I indi-
cation for CRT underwent ce-CMR before device im-
plantation. Eighteen patients (7.6%) were excluded
due to low ce-CMR image quality, moderate/severe
shifting, or artifacts that prevented appropriate LV
segmentation and scar identification. Finally, 217
patients (65.1  10.5 years of age, 71.9% male, 39.6%
ischemic) were included in the study. The device
implanted was a CRT-D in 154 patients (71%) and a
CRT-P in 63 (29%). Baseline clinical characteristics are
summarized in Table 1.Follow-up. Six patients (2.7%) were lost to follow-up
and were excluded from the analysis. During a me-
dian follow-up of 35.5 months (25th to 75th percen-
tiles 12 to 62 months), 25 patients (11.5%) reached the
primary endpoint. Five patients (2.3%) died due to
SCD; 3 of them had a CRT-P device. Twenty patients
(9.2%) received appropriate ICD therapies: 7 received
ICD shocks, and 13 were treated with ATP. There were
no significant differences in baseline clinical charac-
teristics between patients with or without ICD
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therapy/SCD (Table 2). Twelve patients (7.7%)
received inappropriate ICD therapies during follow-
up: 10 inappropriate shocks (8 due to atrial fibrilla-
tion, 1 to electrode noise, 1 to T-wave oversensing)
and 2 inappropriate ATP (1 due to atrial fibrillation, 1
to electrode noise). Among patients with CRT-D in
whom no therapies were programmed in the fast-VT
zone, no episodes of sustained self-limited fast VT
were registered.
Mortality. During follow-up, 46 patients (21.1%) died.
Cardiac death due to refractory heart failure occurred
in 18 patients (39.1%), and SCD occurred in 5 patients
(10.8%). Noncardiac death occurred in 18 patients
(39.1%), and cause of death could not be determined
in 5 patients (10.8%).
ce-CMR ANALYSIS. Late gadolinium enhancement
was observed in 125 patients (57.6%). The proportion
of patients exhibiting myocardial scar was signifi-
cantly higher in those assigned to a CRT-D device
(66.9% vs. 34.9%; p < 0.001).
MYOCARDIAL SCAR SIZE AND CHARACTERISTICS.
All patients that reached the primary endpoint during
follow-up had myocardial scar; in patients without
ICD therapy/SCD, the proportion was 52.1%
(p < 0.001). None of the patients without myocardial
scar experienced ICD therapies or SCD during follow-
up. Additionally, in the subgroup of patients with scar
(n ¼ 125), total scar mass, core mass, and BZ mass
were significantly greater in the group with ICD
therapies or SCD (Table 3). Furthermore, the scar was
not only more extensive, but also more heteroge-
neous (higher BZ mass/total scar mass ratio) in those
patients with ICD therapies or SCD during follow-up
(Table 3).
Seventy-four (59.2%) patients with myocardial scar
exhibited BZ channels within the scar. BZ channels
were observed in all patients with ICD therapies or
SCD, compared with less than one-half (49%) of pa-
tients without ICD therapies or SCD; p < 0.001
(Figure 3). Furthermore, the mass of BZ channels was
significantly higher in patients reaching the primary
endpoint (3.6 3.0 g vs. 1.8 3.4 g; p<0.001) (Table 3).
PREDICTION OF ARRHYTHMIC EVENTS. The cause-
specific hazard model analysis revealed that maleFIGURE 3 Continued
None of these patients experienced ICD therapies or SCD during follow-
magnetic resonance showing a subepicardial inferolateral focal contrast
endocardium to epicardium were created and were color-coded accordin
(A3/B3) 3-Dimensional color-coded signal intensity maps in 5 transmura
the wall thickness. BZ ¼ border zone; ICD ¼ implantable cardioverter-dsex was the only clinical baseline characteristic
associated with ICD therapy or SCD during follow-up
(Table 2). On the other hand, all scar parameters
were significantly associated with the primary
endpoint: scar mass (hazard ratio [HR]: 1.04 [95%
confidence interval (CI): 1.03 to 1.05]; p < 0.001), core
mass (HR: 1.08 [95% CI: 1.05 to 1.1]), BZ mass (HR: 1.06
[95% CI: 1.04 to 1.08]; p < 0.001), and BZ channel
mass (HR: 1.17 [95% CI: 1.1 to 1.25]; p < 0.001).
Three multivariate regression models were created
for scar mass (model 1), BZ mass (model 2), and BZ
channel mass (model 3) (Table 4). Model 1 was
adjusted for LVEF, NYHA functional class, and male
sex. In this model, scar mass was the only indepen-
dent predictor of ICD therapy or SCD (HR: 1.04 [95%
CI: 1.03 to 1.05]; p < 0.001). Model 2 was adjusted for
the same variables, and the only independent pre-
dictor was BZ mass (HR: 1.06 [95% CI: 1.04 to 1.08];
p < 0.001). Finally, model 3 was adjusted for the same
variables, and BZ channel mass was the only inde-
pendent predictor of the primary endpoint (HR: 1.21
[95% CI: 1.10 to 1.32]; p < 0.001).
On the basis of the area under the curve (AUC), scar
mass (AUC ¼ 0.891), BZ mass (AUC ¼ 0.897), and BZ
channel mass (AUC ¼ 0.894) best predicted the pri-
mary endpoint. Scar mass >10 g had 100% sensitivity,
72% specificity, and 30.1% positive predictive value.
Scar mass <10 g, present in 134 (61.7%) of patients,
had 100% negative predictive value for the occur-
rence of a primary endpoint.
A BZ mass >5.3 g had 100% sensitivity, 75% speci-
ficity, and 32% positive predictive value for the pri-
mary endpoint. In 139 patients (64.1%), BZ mass
was <5.3 g; this cutoff value had a 100% negative
predictive value for the occurrence of ICD therapy or
SCD. The cumulative incidence functions showed
statistically significant differences in event-free sur-
vival for primary endpoint related to scar mass and BZ
mass dichotomized by selected cutoff points
(Figure 4).
Finally, in order to identify patients at higher risk
of reaching the primary endpoint, 2 algorithms were
created. A 2-step algorithm based on scar mass >10 g
and the presence of BZ channel identified patients
reaching the primary endpoint with 100% sensitivity,up. (A) Short-axis view, 2-chamber view, and 4-chamber view of contrast-enhanced
enhancement (A1) and a transmural anterior scar (B1). (A2/B2) Concentric layers from the
g to signal intensity (normal myocardium is in purple, border zone in green, and core in red).
l shells were obtained representing the scar, shape, and distribution of the scar tissue across























TABLE 4 Multivariate Competing Risk Regression Analysis for
the Association Between Clinical and ce-CMR Parameters and the
Study Endpoint of ICD Therapy or SCD
HR (95% CI) p Value
Multivariate model 1
Scar mass, g 1.04 (1.03–1.05) <0.001
Sex 0.70 (0.19–2.63) 0.602
LVEF, % 0.99 (0.93–1.04) 0.621
NYHA functional class I–II vs. III–IV 0.46 (0.19–1.13) 0.241
Multivariate model 2
BZ mass, g 1.06 (1.04–1.08) <0.001
Sex 0.57 (0.16–2.06) 0.389
LVEF, % 0.98 (0.93–1.04) 0.583
NYHA functional class I–II vs. III–IV 0.51 (0.20–1.28) 0.153
Multivariate model 3
BZ channel mass, g 1.21 (1.10–1.32) <0.001
Sex 0.42 (0.12–1.51) 0.185
LVEF, % 1.00 (0.95–1.05) 0.977
NYHA functional class I–II vs. III–IV 0.72 (0.30–1.70) 0.455
p Values in bold are significant.
Abbreviations as in Tables 2 and 3.
Acosta et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . - , N O . - , 2 0 1 7
Scar Characterization for Risk Stratification in CRT Patients - 2 0 1 7 :- –-
8
81.3% specificity, and 36.2% positive predictive value.
The second 2-step algorithm, based on scar mass >10 g
and BZ mass >5.3 g, predicted the primary endpoint
with 100% sensitivity, 79.3% specificity, and 33.3%
positive predictive value (Figure 5). Interestingly, the
proportion of patients that was classified as low risk by
both algorithms was significantly higher in the non-
ischemic cohort versus the ischemic group.Endpoint Cumulative Incidence
100806040
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Scar Mass > 10g Endpoint
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functions for primary endpoint and competitive event depending on scar m
s as in Figure 3.MYOCARDIAL SCAR AND SECONDARY ENDPOINT.
During follow-up, cardiac death occurred in 23 pa-
tients (10.5%): due to refractory heart failure in 18
patients and secondary to SCD in 5 patients. The
presence of scar tissue >10 g was an independent
predictor of the combined secondary endpoint of
cardiac death (due to pump failure or SCD) and ICD
therapy (HR: 5.71 [95% CI: 2.86 to 11.38]; p < 0.001).
Similarly, a BZ mass >5.3 g was independently asso-
ciated with the secondary endpoint (HR: 4.69 [95%
CI: 2.47 to 8.90]; p < 0.001).
ISCHEMIC VS. NONISCHEMIC CARDIOMYOPATHY. The
univariate analysis revealed no significant association
between ischemic cardiomyopathy and the primary
endpoint (Table 2). Although areas of delayed
enhancement were observed in 90.7% of ischemic
patients versus 35.9% of nonischemic patients
(p < 0.001), it was also the case that among patients
with scar, no differences were found in scar mass
(23.5  17.4 g vs. 20.6  30.8 g; p ¼ 0.514), BZ mass
(11.1  11.1 g vs. 11.1  19.1 g; p ¼ 0.999), core mass
(12.5  9.1 g vs. 9.5  12.8 g; p ¼ 0.15), BZ mass/scar
mass ratio (0.41  0.19 vs. 0.42  0.21; p ¼ 0.748), or
BZ channel mass (2.68  3.8 g vs. 1.48  2.7 g;
p ¼ 0.07) between ischemic and nonischemic
patients, respectively.
PREDICTION OF ALL-CAUSE MORTALITY. All-cause
mortality was present in 46 patients, of which 23
(50%) died due to cardiovascular causes (heart failureBZ Mass <5.35g Competitive Event
BZ Mass >5.35g Competitive Event
BZ Mass <5.35g Endpoint
BZ Mass >5.35g Endpoint
100806040
Months
er-Zone Mass and ICD Therapy/SCD-Cumulative Incidence
20
ass (left) and border zone mass (right), stratified by optimal cutoff
FIGURE 5 Algorithms for ICD Therapies/SCD Risk Stratification in Candidates for CRT
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CRT ¼ cardiac resynchronization therapy; NPV ¼ negative predictive value; other abbreviations as in Figure 3.
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TABLE 5 Univariate and Multivariate Cox Regression Analysis for the Association
Between Clinical and Scar Variables With All-Cause Mortality
Univariate
HR (95% CI) p Value
Multivariate
HR (95% CI) p Value
Age 1.03 (1.00–1.06) 0.054 1.01 (0.97–1.05) 0.521
Sex 2.05 (1.04–4.02) 0.037 1.57 (0.79–3.32) 0.236
Ischemic cardiomyopathy 1.92 (1.11–3.32) 0.02 1.99 (1.12–3.53) 0.018
NYHA functional class III–IV 2.23 (1.05–4.76) 0.037 2.48 (1.11–5.6) 0.027
LVEF 0.96 (0.92–0.99) 0.028 0.96 (0.93–1.01) 0.09
LVESV 1.00 (0.99–1.01) 0.182
Diabetes 1.57 (0.88–2.81) 0.123
Atrial fibrillation 2.04 (1.13–3.7) 0.018 1.80 (0.96–3.35) 0.064
GFR 0.98 (0.97–0.99) 0.001 0.98 (0.97–0.99) 0.016
CRT-D vs. CRT-P 1.11 (0.62–1.98) 0.722
Scar mass 0.99 (0.98–1.01) 0.84
Core mass 1.00 (0.98–1.03) 0.829
BZ mass 0.99 (0.97–1.02) 0.616
BZ channel mass 0.97 (0.86–1.09) 0.607
Abbreviations as in Tables 1, 2, and 3.
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10or sudden cardiac death). None of the scar parameters
was significantly associated with all-cause mortality.
In multivariate analysis, ischemic cardiomyopathy
(HR: 1.99 [95% CI: 1.12 to 3.53]; p ¼ 0.018), NYHA
functional class III to IV (HR: 2.48 [95% CI: 1.11 to 5.6];
p ¼ 0.027), and glomerular filtration rate (HR: 0.98
[95% CI: 0.97 to 0.99]; p ¼ 0.016) were independent
predictors of all-cause mortality (Table 5).
DISCUSSION
MAIN FINDINGS. The present study analyzed the
impact of the presence and characteristics of
myocardial scar, assessed by ce-CMR, on the occur-
rence of appropriate ICD therapies and SCD in PP CRT
patients. The main finding was that the extension and
heterogeneity of the myocardial scar were indepen-
dent predictors of ICD therapies/SCD. Specifically, the
optimal cutoff value for the scar mass to predict ICD
therapies/SCD in the long term was 10 g; no
arrhythmic events were observed in patients without
scar or with scar mass <10 g. Furthermore, the pres-
ence of BZ mass >5.3 g or BZ channels were associated
with an additional risk of VA/SCD during follow-up.
CRT-P VS. CRT-D IN PP PATIENTS: RISK STRAT-
IFICATION. No randomized controlled trial to our
knowledge has been conducted to date to compare
CRT-P versus CRT-D in PP patients. Therefore, the
benefit of adding backup ICD capabilities in patients
with class I indication for CRT is unknown. In the
COMPANION (Comparison of Medical Therapy, Pac-
ing, and Defibrillation in Heart Failure) study, only
CRT-D was significantly associated with reduction inSCD (1). However, the study was not designed to
compare CRT-D versus CRT-P with the specific
endpoint of VA or SCD. On the other hand, long-term
results of the CARE-HF (Cardiac Resynchronization-
Heart Failure) trial showed a significant 5.6% reduc-
tion in SCD risk with CRT-P (11), suggesting that,
although the benefit of CRT on heart failure mortality
is observed at short-/mid-term, the reduction of SCD
risk requires longer follow-up periods.
Given that life-threatening VA has a low incidence
in PP CRT patients (1,4), better risk-stratification tools
are required. This study showed that the absence of
myocardial scar or a scar mass <10 g identified pa-
tients at low risk of ICD therapies/SCD during long-
term follow-up. Additionally, scar heterogeneity
represented an independent predictor of life-
threatening arrhythmic events, suggesting the
potential utility of scar characterization for risk
stratification in CRT patients. In the present study,
scar characterization was performed both quantita-
tively (quantification of BZ mass and BZ mass/scar
mass ratio) and qualitatively (identification of BZ
channels). Both methods were useful for predicting
arrhythmic events. With respect to quantitative
analysis, patients reaching the primary endpoint
showed more extensive BZ tissue and higher values of
BZ mass/scar mass ratio. On the other hand, patients
with ICD therapies/SCD also exhibited higher values
of BZ constituting BZ channels. In the present study,
although the AUC values of BZ mass and BZ channel
mass for predicting the primary endpoint were
similar, all patients with appropriate ICD therapies or
SCD during follow-up showed BZ channels within the
scar, suggesting that the BZ distribution creating BZ
channels may be more closely related to arrhythmic
events than the transitional BZ between core and
healthy tissue. Indeed, the algorithm based on scar
mass >10 g and the presence of BZ channels identified
patients reaching the primary endpoint with a slightly
higher specificity (81.3%) than the algorithm based on
scar mass >10 g and BZ mass >5.3 g (79.3%) (Figure 5).
Currently, the decision to implant an ICD is pri-
marily based on the presence of severe LV dysfunc-
tion. However, in the present study, none of the
multivariate models (Table 4) showed LVEF as an
independent predictor of ICD therapies or SCD. This is
consistent with prior studies reporting that LVEF
lacks both sensitivity and specificity in predicting
life-threatening arrhythmias (12). On the other hand,
the results of the present study highlight the poten-
tial of ce-CMR-based scar characterization to improve
the specificity of risk stratification by identifying pa-
tients with CRT indication (thus, with severe LV
dysfunction) at low risk of life-threatening
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Scar character-
ization by ce-CMR predicts appropriate ICD therapies and SCD in
primary prevention CRT candidates.
TRANSLATIONAL OUTLOOK: A randomized study is required
to confirm the usefulness of scar characterization for the iden-
tification of CRT candidates that could benefit from adding
defibrillator capabilities to the CRT device.
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11arrhythmias. This has been corroborated by a recent
meta-analysis by Disertori et al. (13) reporting that
late gadolinium enhancement was a powerful pre-
dictor of ventricular arrhythmias, irrespective of
ischemic and nonischemic etiology, especially when
LVEF was #30%.
Finally, both scar mass >10.0 g and BZ mass >5.3 g,
not only predicted the primary endpoint, but also
were significantly associated with the secondary
combined endpoint of ICD therapy and cardiac mor-
tality. However, none of the scar parameters was
associated with all-cause mortality, suggesting that
CMR-based tissue characterization could be useful for
the prediction of specific cardiac outcomes (cardiac
mortality and life-threatening arrhythmias) in CRT
patients. The association between scar burden and
mortality has been widely studied in ischemic pa-
tients. Studies by Kwon et al. (14) and Yan et al. (15)
showed that delayed enhancement and scar hetero-
geneity were powerful predictors of mortality in
ischemic patients. On the other hand, Demirel et al.
(16) reported that scar characteristics predicted
arrhythmic outcomes (sustained VT or ICD therapy)
but was not independently associated with all-cause
mortality. The present study included both ischemic
and nonischemic CRT patients. Furthermore, 50% of
deaths were due to noncardiac causes. Although
these differences in patients’ characteristics and
causes of death between this study and previous ones
could explain the discrepancies observed in the as-
sociation between scar characteristics and all-cause
mortality, it should be acknowledged that ascertain-
ment of the cause of death is often problematic.
STUDY LIMITATIONS. The main limitation of this
study is the low incidence of the primary endpoint,
although it was similar to that in larger studies
previously published. In 5 patients, 3 of them with a
CRT-D device, the cause of death could not be
determined; the mean length of follow-up in these
patients was 28.4 months (interquartile range: 18 to
39 months), and no arrhythmic event was recorded.
Although the mean follow-up period of the present
study (35.5 months) is longer than that in the majority
of recent studies dealing with the issue of CMR-based
risk stratification, the results should be confirmed in
larger cohorts with longer follow-up periods. Another
potential limitation is the fact that images were
acquired either using a 1.5-T or a 3-T clinical scanner,
because it remains unknown whether quantitative
thresholds of late gadolinium enhancement are
interchangeable among different strength scanners.
In terms of the study endpoints, programming or notICD therapies in the fast-VT zone was left to the
discretion of the treating physician. However, this
programming is consistent with current clinical
practice, which makes the results obtained in the
present study directly applicable to real-world pa-
tients. The primary endpoint was defined as the
composite of appropriate ICD therapy (ATP or shock)
or SCD, in order to include all potential life-
threatening VAs observed in the study cohort. It
should be acknowledged that ICD shocks and ATP are
not equivalent. Furthermore, there are limitations in
using appropriate ICD therapies as a surrogate for
SCD. Our definition of primary endpoint is consistent
with previous studies on this subject (7,17,18),
although it is also the case that other authors did not
include ATP as a primary endpoint (12,19,20). It is also
possible that self-limited episodes of VT could have
been missed in CRT-P patients; however, the clinical
relevance of this kind of episode is not well estab-
lished. Finally, although this was a multicenter study,
there is a need for confirmation of these results with a
larger patient population and external validation of
ce-CMR post-processing method and analysis.
CONCLUSIONS
The presence, extension, heterogeneity, and qualita-
tive distribution of BZ tissue of myocardial scar
independently predict appropriate ICD therapies and
SCD in CRT patients. Algorithms based on scar mass
and BZ distribution or extension correctly identify
patients at low risk of life-threatening VAs. These
findings warrant future prospective studies for
external validation.
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